Developing organoids were then subjected to a panel of morphogen treatments with varying timing, concentration and combination of the molecules CHIR99021 (CHIR, WNT pathway activator), XAV939 (WNT pathway inhibitor), rh-SHH/CS24II (SHH) and purmorphamine, FGF-8B (FGF8), RA, rhBMP-4 (BMP4), rhBMP-7 (BMP7)
